Search This Blog

Thursday, April 30, 2026

Can-Fite positive Phase 2a data for namodenoson in advanced pancreatic cancer

 

Can-Fite BioPharma reports positive Phase 2a data for namodenoson in advanced pancreatic cancer with durable disease stabilization

  • Namodenoson demonstrated a favorable safety profile in advanced pancreatic cancer patients in the Phase 2a trial.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)